Navigation Links
Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
Date:10/9/2007

FREDERICK, Md., Oct. 9 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the Australian Therapeutic Goods Administration has cleared ActiPatch for sale by its distributor, Endotherapeutics Party Limited.

"We are confident that the experienced sales professionals of Endotherapeutics will successfully launch ActiPatch in the Australian market. Endotherapeutics' team has many decades of experience in the medical devices market and their people come from well known established medical devices companies," said Andrew Whelan, President of BioElectronics Corporation.

Ivan Srejber, Managing Director of Endotherapeutics Party Limited, said "We have extensive experience in launching products and establishing significant market share for previously unknown products. We are very excited about the market potential for ActiPatch in Australia and look forward to a mutually beneficial business partnership with BioElectronics Corporation."

About Endotherapeutics Party Limited:

Founded in 1998, Endotherapeutics has provided medical technologies for the health care specialist throughout Australia. Companies represented by Endotherapeutics are leaders in their specific market segments. To learn more about Endotherapeutics Party Limited please visit http://www.endotherapeutics.com.au.

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Imago provides atomic probe to Australian lab
2. Australian company will sell TeraMedicas medical imaging software
3. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
4. Third Wave seeks approval of Cystic Fibrosis test
5. Kyron wins FDA approval for brain imaging technology
6. SGI receives court approval for bankruptcy motions
7. FDA programs encourage and expedite drug development and approval
8. UW-Stevens Point Professor Receives Patent Approval For New Technology
9. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
10. 140-Fold Increase of Protein Achieved in Pichia Fermentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Applied BioMath ( ... modeling to drug research and development, today ... Zymeworks Inc. for quantitative systems pharmacology (QSP) ... for the treatment of cancer. ... for GLP toxicology studies and first-in-human dose ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... for cell-based assays, disperses a quarterly travel award to noteworthy scientists who will ... company announced that its new round of awards are being given to two ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... Forecast to 2025" report to their offering. ... The Global Agricultural Chelates Market ... the next decade to reach approximately $825.4 million by 2025. ... for all the given segments on global as well as regional ...
(Date:3/29/2017)... -  GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") announced ... stratification test for breast cancer, via its Virginia ... incorporates a blood-based biomarker test with a sophisticated algorithm to ... cancer.   ... BreastSentry measures the fasting plasma levels of two biomarkers ...
Breaking Biology Technology:
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification ... Used combined in one project, multi-biometric solutions provide a ... ...
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
Breaking Biology News(10 mins):